ReviewTranslational oncology2021
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Dawn C Janysek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this paperpooled ittrialcites it